AI in transportation

Showing 3613 articles
Business

Bausch Health's Deep Discount: Market Overshoot or Justified Skepticism?

With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.

Business

Atlassian's Steep Slide: Is the Collaboration Giant Now a Value Play?

After a punishing 61% decline in its share price over the past year, Atlassian finds itself at a critical juncture. With the stock trading near $118, investors are grappling with whether this represents a profound disconnect from long-term potential or a justified reassessment of growth prospects in a shifting market.

Business

Greenlight Capital Bets Big on New Coal Giant Core Natural Resources Post-Merger

Greenlight Capital has spotlighted Core Natural Resources (CNR), the entity formed from the merger of Arch Resources and CONSOL Energy, as a key coal investment. The fund cites the company's valuation and combined asset base, even as the sector grapples with operational challenges. This endorsement brings renewed scrutiny to CNR's integration path and its strategy in a complex market.

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

Amcor's Stock Rebound: A Sign of Value or a Market Miscalculation?

Amcor's shares have rallied over 6% in the past month, sparking debate among investors. While a discounted cash flow model suggests significant undervaluation, its elevated P/E ratio tells a conflicting story. We examine the metrics and the broader packaging sector's challenges to assess the opportunity.